these eight patients were under the age of 20. In the cases found in the literature, the development of pancreatic pseudocysts occurred during both early and late treatment and was independent of VPA dose and titer. Conservative treatment of the cyst was administered in seven of eight cases; in one patient the pseudocyst was primarily treated surgically.
To date, there is no literature reporting a VPA-associated pancreatic hemorrhagic pseudocyst as a severe complication of treatment.
We herein report a case of an acute, large hemorrhagic pseudocyst in a patient with pancreatitis after exposure to VPA who responded successfully and dramatically to percutaneous catheter drainage as the sole therapeutic management. A literature review of pancreatitis after VPA treatment revealed a small number of patients with pancreatic pseudocysts and a few cases involving hemorrhagic pseudocysts. showed multifocal peripancreatic fat infiltration, a large flu- 
DISCUSSION
We herein describe an extremely rare case of VPA associated with hemorrhagic pseudocyst. VPA is the most widely used first-generation antiepileptic drug, and is prescribed predominantly in epilepsy and psychiatric disorders. VPA has good efficacy and pharmaco-economic profiles, as well as a relatively favorable safety profile; 6 however, adverse drug reactions have been reported in relation to VPA use, either in monotherapy or polytherapy with other antiepileptic drugs. In particular, it is likely the most frequent cause of drug-induced acute pancreatitis. [7] [8] [9] [10] The association between acute pancreatitis and VPA therapy was first described in 1979 by Batalden et al. 11 and Camfield et al. 7 Since 1979, several single-case reports or case series have been reported.
Among these, the study of Sinclair et al. 12 showed that the dose of VPA, duration of treatment, serum VPA level, generic preparation, and the presence of concomitant antiepileptic drugs did not seem to be risk factors for acute pancreatitis. These findings suggested that the mechanism of toxicity likely involves metabolic idiosyncrasy, which is mediated by aberrant VPA metabolism. 2 In general, the development of drug-induced pancreatitis has been linked to more than 55 different drugs. Specifically, drug-induced pancreatitis is possibly caused by azathioprine, furosemide, tetracycline, metronidazole, isoniazid, rifampicin, VPA, sulphonamides, cyclosporine, and some antineoplastic drugs.
In our case, there were no other causes (infection, trauma, obstruction, hypercalcemia, hypertriglyceridemia, or use of other medications) explaining acute pancreatitis, and it was thought to be due to VPA therapy.
The largest study 13 investigating the risk factors for VPAinduced pancreatitis demonstrated that pancreatitis was found to be more frequent in young patients with polytherapy and that pancreatitis occurred primarily during the first year after initiation of VPA therapy. This study is not in concordance with our case, which pertained to a patient was not in the most-affected age group. In addition, the patient was using VPA monotherapy at the appropriate dose 
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